UK cuts ribbon on £60 million facility to boost cell and gene therapy industry

23 April 2018

CGT Catapult, part of a UK government-led industry-boosting initiative, has unveiled a new cell and gene therapy manufacturing center in Stevenage, about 30 miles north of London.

Backed by over £60 million ($84 million) of government money, the facility is designed to support and develop the nascent cell and gene therapy industry in the country.

Operating according to Good Manufacturing Practice (GMP) standards for clinical product manufacturing, the center will help supply a network of Advanced Therapies Treatment Centers (ATTCs) formed as part of a government plan to invest £146 million in medicines manufacturing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK